Omega-3 (heart).

The long-chain fats in fish oil carry several double bonds that oxidize easily, and vitamin E is the fat-soluble antioxidant that sits in the same oil and takes the hit for them, halting the chain reaction before the fatty acids are damaged. It is why fish oil softgels almost always include added tocopherol, and why eating more of these fats raises the body's need for vitamin E.

Astaxanthin is a deeply pigmented antioxidant that dissolves into the same fatty phase as the omega-3s and neutralizes the free radicals that would otherwise attack their double bonds. Krill oil carries the two together in nature, and the pairing is used to keep the delicate omega-3 oil from oxidizing both on the shelf and once it is absorbed.

CoQ10 is a fat-soluble molecule the gut absorbs poorly on its own, so taking it within an oil like fish oil provides the lipid matrix that improves its uptake. The two are common partners in cardiovascular formulas, where the omega-3s settle into heart-muscle cell membranes and CoQ10 supports the mitochondria that power that same muscle.

Cholecalciferol needs a lipid carrier to enter the micelle and the chylomicron, and the oil provides it. That co-absorption is why the two share cardiovascular formulas.

GLA elongates to DGLA and part of it can push on to arachidonic acid, a conversion EPA restrains. Formulating them together keeps the omega-6 arm at DGLA rather than further along.

Nicotinic acid reduces hepatic VLDL output and free fatty acid release from adipose tissue, while EPA and DHA lower triglyceride synthesis and raise fatty acid oxidation in the liver. The mechanisms are separate, which is why the combination sits in lipid-support formulas.

Monacolin K slows cholesterol synthesis at HMG-CoA reductase, a step omega-3 does not touch, while EPA and DHA act on triglycerides. CoQ10 synthesis shares the same mevalonate pathway monacolin slows, which is why CoQ10 usually joins the pair.

Ascorbate regenerates oxidised vitamin E, and vitamin E protects the double bonds in EPA and DHA from peroxidation. The link runs through tocopherol rather than acting on the oil directly.

Glutathione peroxidase is a selenoenzyme that reduces the lipid hydroperoxides forming on polyunsaturated chains, so selenium adequacy sits under an omega-3 load.

EPA lowers thromboxane A2 by displacing arachidonic acid while ginkgolides act on platelet activating factor signalling. Both move normal platelet aggregation in the same direction.

Garlic organosulfur compounds reduce platelet aggregation on their own route, adding to the thromboxane shift EPA produces. Both are staples of cardiovascular formulas, so the stacking is common.

Salicylate dampens cyclooxygenase-derived thromboxane, the same output EPA reduces through substrate competition, so the two converge on one step of normal clotting.

DHA is carried and stored largely as phosphatidylcholine, so choline supply governs how the fatty acid is packaged into circulating lipoproteins.

Free iron initiates Fenton-type peroxidation of polyunsaturated chains, and marine oil is the most peroxidation-prone lipid to sit beside it. Formulators separate the two dosage forms.

Magnesium is a cofactor for the sodium-potassium ATPase that maintains the resting membrane potential of cardiac muscle, while EPA and DHA change the fatty acid composition of the membrane those channels sit in. The two act on the same tissue from different angles. No combination trial in the candidate set measures them together.

Potassium gradients set the repolarisation phase of the cardiac action potential, and long-chain omega-3s incorporate into the phospholipid bilayer surrounding those ion channels. Each supports normal rhythm through a distinct route. The pairing is mechanistic rather than trial-backed.

Taurine is one of the most abundant free amino acids in heart muscle and participates in calcium handling and osmoregulation there. Omega-3 fatty acids remodel the membrane in the same tissue. They are complementary rather than overlapping, and the combination has not been measured here.

Long-chain fatty acids, EPA and DHA included, cannot cross the inner mitochondrial membrane without being esterified to carnitine by CPT1 and carried by the carnitine-acylcarnitine translocase. Carnitine availability is therefore upstream of the beta-oxidation of any long-chain fat. This is textbook transport biochemistry, not an outcome claim.

EPA and DHA carry five and six double bonds and oxidise readily, both in the bottle and once incorporated into membranes. Chain-breaking antioxidants of the vitamin E family sit in the same lipid phase and interrupt lipid peroxidation. This protects the oil rather than adding a separate physiological effect.

Phospholipids emulsify fish oil into finer droplets, giving bile salts and lipase more surface to work on before micelle formation. Krill-derived omega-3 arrives naturally in phospholipid form for the same reason. The claim is about delivery of the oil.

Triglyceride and ethyl ester omega-3 both require hydrolysis before absorption, and the ethyl ester form depends on pancreatic lipase more heavily, which is why it absorbs better with a fat-containing meal. Reduced fat digestion reduces the fraction taken up. Ordinary digestive physiology.

DHA is carried in the body largely within phosphatidylcholine species, and lysophosphatidylcholine-DHA is a recognised transport form across certain membranes. Supplying phospholipid alongside the oil matches the way the body moves it. Human head-to-head data on supplemental pairing is limited.

Both influence how readily blood clots, omega-3 through platelet eicosanoid balance and nattokinase through fibrinolytic activity. Stacking two agents acting on clotting compounds the effect, which is worth flagging to anyone already on anticoagulant medication. This is a caution, not a benefit pairing.

Gingerols inhibit thromboxane synthesis, the same eicosanoid arm that EPA shifts toward the less aggregatory 3-series. Combining them adds two pushes in the same direction on platelet aggregation. Flag it before surgery or alongside anticoagulant medication.

Vitamin K is the cofactor for gamma-carboxylation of clotting factors II, VII, IX and X, while omega-3 shifts platelet eicosanoids the other way. They are not cancelling each other in any simple sense, but they act on different limbs of haemostasis and both matter to anyone whose clotting is being managed medically. Worth surfacing as an interaction rather than a benefit.

Dietary nitrate is reduced to nitrite and then nitric oxide by an enterosalivary route, supporting normal vasodilation, while omega-3 fatty acids act on endothelial membrane composition and eicosanoid signalling. The levers are independent. No combination trial in this candidate set measures them together.

Citrulline is converted to arginine in the kidney and feeds endothelial nitric oxide synthase, a different entry point to vascular tone than membrane fatty acid remodelling. Combining them targets the endothelium from two directions. Support is mechanistic.

Psyllium forms a viscous gel that binds bile acids and increases their faecal loss, prompting the liver to draw on cholesterol to replace them. Omega-3 acts instead on hepatic triglyceride output. Different arms of normal lipid handling, so the effects are not redundant.

Plant sterols displace cholesterol from mixed micelles in the gut lumen, reducing the fraction absorbed. Omega-3 works downstream in the liver on triglyceride-rich lipoprotein secretion. Because the sites differ, the effects on normal blood lipid levels are plausibly additive.

Berberine acts largely through LDL receptor expression and AMPK signalling, while omega-3 reduces hepatic VLDL triglyceride output. Non-overlapping mechanisms are the usual reason for pairing them. The combination is not measured in the candidate literature here.

A comparative review examined dietary protein, creatine and omega-3 against muscle strength, endurance and recovery measures, placing them as separate levers on the same tissue. Creatine acts on phosphocreatine resynthesis while omega-3 alters membrane composition and inflammatory signalling after exercise. The review compares rather than combines them, so read it as a rationale rather than a measured synergy.

The same comparative review sets dietary protein beside omega-3 for muscle strength and recovery measures. Protein supplies the amino acid substrate for muscle protein synthesis. Omega-3 has been described as changing the sensitivity of that response. Combination effects were not the design of that work.

Curcumin is characterised against NF-kB and COX-related signalling, while EPA competes with arachidonic acid at the same enzymes as a substrate. The overlap means the two may reinforce each other on inflammatory markers. Markers, not clinical outcomes, and no combination trial is cited here.